Visit the NEW CoM Homepage |  University of Kentucky |  UK HealthCare |  Give to Medicine |  Diversity  
UK College of Medicine logo Link to the College of Medicine web site
  • ed5
  • rs3
  • cs2
  • ad4

Barnstable Brown Kentucky Diabetes and Obesity Center



Gregory Graf, Ph.D.

Picture of Dr. Graf   

          Associate Professor, Pharmaceutical Sciences, College of Pharmacy

Contact Information

Training and Publications

University of Kentucky Research Summary (PDF)
Room 434 College of Pharmacy Building Publication Listing on PubMed
725 Rose Street  
Lexington, KY 40536-0082  
Telephone: 859-257-4749  
Fax: 859-257-7564  

Research Interests

Dr. Graf's laboratory's research focus is on the relationships between obesity and changes in lipid and lipoprotein metabolism that link obesity to cardiovascular diseases and diabetes.

We have two main areas of research. The first of these projects focuses on the active elimination of cholesterol from the body in a process termed “Reverse Cholesterol Transport”. Currently available therapies target cholesterol synthesis and absorption to reduce plasma cholesterol and lower the risk cardiovascular disease. However, an emerging body of work suggests that the flux of cholesterol through lipoproteins (LDL and HDL) is more relevant to cardiovascular disease than their absolute levels in plasma. In addition, research from our lab and others suggests that cholesterol in the liver may play an active role in the development of non-alcoholic fatty liver disease, a common complication of obesity.

A transport protein complex called ABCG5 ABCG8, or G5G8 for short, is expressed in both the liver and intestine and represents the major route for cholesterol elimination from the body. We have recently shown that the loss of this transporter worsens the development of fatty liver disease and that acutely increasing its levels can restore some aspects of liver function in a mouse model of obesity and fatty liver disease. However, little is known about what regulates the activity of this cholesterol “pump”. The goal of this project is to determine how this pump is regulated such that therapeutics can be developed to accelerate cholesterol elimination in the treatment of both cardiovascular and liver disease.

The second project focuses on the role that fat, or adipose tissue, plays in the development of obesity-related metabolic disorders. Adipose tissue was once thought to simply be a storage organ, but work over the last decade has demonstrated that it plays a pivotal role in the development of insulin resistance, systemic inflammation and increased risk of cardiovascular disease and Type 2 diabetes. Using a unique model of rapid-onset obesity and insulin resistance, we conducted experiments to evaluate changes in gene expression in adipose tissue. The two major pathways disrupted in this model are involved in the regulation of biological rhythms and in lung development. These results suggest that the adipose tissue of obese mice is asynchronous with the rest of the body and that fat cells may undergo genetic reprogramming during the development of adipose dysfunction. Experiments are ongoing to determine if these pathways are casual bystanders during the development of adipose dysfunction or play a causative role. If the latter is true, these pathways will be explored further to determine if therapeutics that target these pathways would be useful in the treatment of obesity-related metabolic diseases.

Comments and Corrections |  An Equal Opportunity University |  Jobs  |  Terms, Conditions and Accessibility Statements   |  Privacy
© 2012, University of Kentucky College of Medicine, 138 Leader Ave., Lexington, Kentucky, USA 40506-9983
Student Affairs: (859) 323-5261 · Admissions: (859) 323-6161 · Clinical Questions: (859) 257-1000 · Dean's Office: (859) 323-6582
Page last updated Thursday, September 13, 2012